Introduction
Although both CD4 + and CD8 + T lymphocytes are involved in the immune response against cancer and viral infections, there has been a preferential attention to the antitumor responses mediated by MHC class Irestricted, CD8 + T lymphocytes. This focus on CD8 + T lymphocytes stems from experimental data showing that (i) many tumors express MHC class I but not MHC class II molecules 1 and (ii) CD8 + T lymphocytes are capable to directly kill tumor or virally infected cells upon recognition of MHC-presented antigenic peptides. 2 Moreover, (clinical) adoptive immunotherapy studies demonstrated that the transfer of viral or tumor-reactive CD8 + T lymphocytes can result in effective antiviral and antitumor responses, respectively. [3] [4] [5] [6] [7] In addition, vaccination studies using MHC class I immuno-dominant peptides have shown that protective antitumor immunity can be generated. 8, 9 On the other hand, the important role of CD4 + T lymphocytes in the induction and persistence of effective immunity was demonstrated in studies using CMV-specific CTL clones as well as CD4 knockout mice. [10] [11] [12] [13] [14] [15] After adoptive transfer of CMV-specific CD8 + CTL to patients, which lacked CD4 + CMV-specific T lymphocytes, the CD8 + T-cell response to CMV declined, suggesting an essential role for CD4 + T-helper lymphocytes in the persistence of the transferred CD8 + CTLs. 10, 11 The efficacy of the infused CD8 + CTL was improved by the coadministration of the Th1-type cytokine IL-2, supporting the notion of collaborations between CD4 and CD8 T cells. 11 Furthermore, mice deficient for CD4 were shown to be unable to maintain lymphocytic choriomeningitis virus (LCMV)-specific CD8 + CTL or clear virus following a challenge with low-dose LCMV. 12 Additionally, the induction of tumorspecific CTL against autologous MHC class II-negative effusion-associated mononuclear cell tumors was shown to be severely impaired, indicating that CD4 + T lymphocytes are essential for the induction of protective antitumor CD8 + CTL. 16 Adoptive transfer of CD4 + tumor-specific T lymphocytes may therefore be clinically relevant for effective antitumor responses. Indeed, in mice, the adoptive transfer of activated MHC class IIrestricted, tumor-specific CD4 + T lymphocytes has resulted in de novo generation of tumor-specific CD8 + T lymphocytes and effective antitumor responses. 17 In addition, adoptive transfer of vesicular stomatitis virus-specific (VSV) CD4 + T lymphocytes into mice confered protection against infection with a vaccinia virus expressing the VSV-G protein. 18 Nevertheless, the generation of tumor-specific MHC class II-restricted CD4 + T lymphocytes is hampered by the lack of well-defined MHC class II-binding peptides. Powerful techniques, such as reversed immunology, used to identify MHC class I-restricted peptide epitopes 19 are not yet available for the identification of MHC class II-binding peptides. Moreover, the isolation of tumor-specific MHC class II-restricted CD4 + T lymphocytes from individual patients is troublesome and unpredictable, and hence limits its clinical application.
We have recently demonstrated the reproducible and efficient transfer of HLA-A1-restricted, MAGE-A1-specific chimeric T-cell receptor (TCR) genes to bulk cultured primary human T lymphocytes. 20 Chimeric single-chain-and two-chain TCR coupled to CD3-z were functionally expressed on CD8 + T lymphocytes and have the advantage that they do not associate with endogenous TCR ab chains, when compared with full-length TCR ab. 20, 21 Upon incubation with HLA-A1 + , MAGE-A1 + melanoma cells, these transduced T lymphocytes were specifically activated to lyse the relevant tumor cells and to produce cytokines. In this study, we addressed whether CD4 + T lymphocytes can be grafted with MHC class I-restricted tumor specificity so that triggering via the MHC Class I-restricted TCR induces CD4 helper functions. We demonstrate that primary activated CD4 + T lymphocytes can be efficiently retargeted to HLA-A1-restricted, MAGE-A1 + melanoma cells by retroviral introduction of an HLA-A1/MAGE-A1-specific chimeric two-chain TCR/z. However, only upon introduction of both the CD8a gene and the tcTCR/z genes, CD4 + T lymphocytes acquire the capacity to specifically bind to HLA-A1/MAGE-A1 complexes. In the case of CD8 + T lymphocytes, the CD8 molecule participates in the activation of these T lymphocytes by binding to the same peptide-MHC complex as does the TCR. 22, 23 The role of CD8 may be two-fold: (A) stabilizing the interaction between TCR and peptide-MHC complex and enhancement of the T-cell activation by increasing the t 1/2 of the TCR/CD8/peptide-MHC complex; 24 (B) recruitment of CD8/p56lck to the TCR/CD3/z complex, which is essential for early signaling events in the T lympohocytes. 25, 26 We demonstrated that CD4 
pered by the difficulty to identify MHC class II-restricted tumor epitopes that can be used for their in vitro stimulation. Reproducible technologies for the identification of MHC class I-presented tumor antigens have been developed, 19 but these are lacking for class II-presented tumor antigens. 27 Owing to the fundamental differences in peptide processing and loading of the MHC class II molecules, when compared to MHC class I molecules, identification of class II-presented tumor peptides awaits a technical breakthrough. 27, 28 Despite technical difficulties, the availability of CD4 + T lymphocytes is of importance because CD4 + T lymphocytes play critical roles in the generation of antigen-specific T-cell responses and in the induction of memory, providing sustained immunity. [13] [14] [15] [16] [17] [18] Recently, we and others successfully grafted primary human T lymphocytes with MHC class I-restricted specificity through introduction of full-length TCR ab, chimeric single-chain and two-chain TCR genes. Introduction of these (chimeric) TCR conferred the T lymphocytes with a new MHC-restricted tumor specificity. 20, [29] [30] [31] The physiological interaction between TCR ab on T lymphocytes and MHC class I molecules on target cells may depend on the simultaneous interaction of CD8a and/or CD8b on T lymphocytes with the MHC class I molecules on target cells. [32] [33] [34] In fact, addition of anti- 
TCR transfer to CD4
+ cells requires CD8a R Willemsen et al CD8 mAbs generally inhibits T-cell-mediated immune functions 33, 35 or specific binding of soluble MHC class I tetramers. 36 We addressed the question whether CD4 + /tcTCR/z + T lymphocytes, were able to bind tetramers and exerted tcTCR/zmediated immune functions, that is, cytokine production and lysis of tumor cells. The cytokines IL-2, IFN-g and TNFa were produced only after specific stimulation with the relevant MAGE-A1/HLA-A1-expressing target cells. We conclude that triggering of the HLA-A1/MAGE-A1-specific immune response required the coexpression of CD8a and the tcTCR/z. Indeed, the tcTCR/z-mediated target cell lysis and binding of tetramers was inhibited by the addition of anti-CD8 mAb (Figures 4b and 2c,  respectively) . CD4 + primary human T lymphocytes grafted with MHC-antigen-independent, antibody-based scFv/z or scFv/g receptors were also shown to be responsive to their relevant target antigen-expressing tumor cells. 37, 38 These scFv-receptor-expressing T cells also mediated cytolysis of antigen-positive target cells and produced TNFa and IFNg. However, IL-2 secretion was only observed when the scFv/z-receptor expressing cells were stimulated through their endogenous TCR, and not when stimulated through the antibody-based receptor. 37 This difference in capacity to produce IL-2 between tcTCR/z-expressing cells and scFv/z-expressing cells may reflect differences in the capacity of these receptors to recruit multiple src kinase signaling molecules, phosphorylation of the receptors and eventually amplification of the receptor-mediated signals.
In mice, adoptive transfer models of viral infections such as influenza and VSV have demonstrated that the 
Materials and methods

Cells and antibodies
T lymphocytes derived from healthy donors were isolated and expanded as described elsewhere. 40 PE (CoulterImmunotech, Marseille, France). HLA-A1/MAGE-A1 tetramers were kindly provided by P van der Bruggen (Brussels, Belgium).
Construction of retroviral vectors and transduction of primary human T lymphocytes
The chimeric TCR VaCaz and VbCbz genes were derived from the CTL clone MZ2-82/30 as described previously. 20 The CD8a gene was amplified with primers that allowed introduction into the retroviral vector pBullet, from the pLCD8aSH vector (a kind gift from Jos Molenhorst, Leiden, the Netherlands). Chimeric TCR genes and the CD8a gene were introduced into populations of anti-CD3 mAb-activated primary human T lymphocytes, which were either depleted with antiCDa mAb-coated magnetic beads or used directly, essentially as described. 20 After two rounds of supernatant transduction, the transduced T lymphocytes were expanded in culture medium, supplemented with r-IL2 (360 IU/ml). All experiments were performed with primary human T lymphocytes obtained from at least five healthy donors. , starting with CD8a-depleted or nondepleted lymphocyte populations. FACS-sorted lymphocytes were expanded prior to their use in functional assays as described. 20 
TNF-a, IFN-g and IL-2 production
To quantify TNF-a, IFN-g and IL-2 production by the transduced flow-sorted human T lymphocytes, 6 Â 10 4 transduced T lymphocytes were cultured for 24 h either in the presence or absence of 2 Â 10 4 adherent tumor cells in RPMI-1640 medium supplemented with 360 IU/ml rIL-2, and where indicated, with 10 mg/ml MAGE-A1 peptide. At the end of culture, supernatant was harvested and the levels of TNF-a, IFN-g and IL-2 (CLB, Amsterdam, the Netherlands) were measured by standard ELISA according to the manufacturer's instructions.
Cytotoxicity assays
Cytolytic activity of transduced human T lymphocytes was measured in 51 Cr-release assays as described previously. 20 Peptide loading of target cells was performed by adding MAGE-A1 nonapeptide (EADPTGHSY, Leiden University Medical Center, the Netherlands) or irrelevant HLA-A1-binding Influenza peptide (CTELKLSDY, Leiden University Medical Center, the Netherlands) at the indicated concentrations to the target cells 5-15 min prior to incubation with effector T lymphocytes. The mAb anti-CD8a (10 mg/ml final) was added to the melanoma target cells 5 min before incubation with the T lymphocytes. Effector and target cells were cultured at the indicated E:T ratios. The incubation period of effector and target cells is indicated in the figures. Percentage specific 51 Cr release was calculated as follows: ((test counts À spontaneous counts)/ (maximum counts À spontaneous counts)) Â 100%.
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